1. 1) Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int., 31 (Suppl. 1), 111–116 (2011).
2. 2) “WHO|Hepatitis B.”: ‹http://www.who.int/mediacentre/factsheets/fs204/en/›, accessed 20 April, 2020.
3. 3) Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736–1788 (2018).
4. 4) Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D, Venzon DJ, Amano M, Higashi-Kuwata N, Aoki M, Delino NS, Hayashi S, Takahashi S, Sukenaga Y, Haraguchi K, Sarafianos SG, Maeda K, Mitsuya H. 4′-Modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology, 62, 1024–1036 (2015).
5. 5) Kohgo S, Yamada K, Kitano K, Iwai Y, Sakata S, Ashida N, Hayakawa H, Nameki D, Kodama E, Matsuoka M, Mitsuya H, Ohrui H. Design, efficient synthesis, and anti-HIV activity of 4′-C-cyano- and 4′-C-ethynyl-2′-deoxy purine nucleosides. Nucleosides Nucleotides Nucleic Acids, 23, 671–690 (2004).